He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Earlier this year, when US President Donald Trump offered to buy Greenland from Denmark, online rumours circulated that the Danish government might encourage Novo Nordisk, the Danish company behind ...

A new study has found that a once-weekly injection of semaglutide, a medication originally developed for diabetes and weight ...

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

Although the trial results failed to meet Novo Nordisk’s projection of 25% weight loss, the Denmark-based drugmaker said it plans to seek regulatory approval of CagriSema in early 2026.

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

Investing.com -- U.S. pharmaceutical company Eli Lilly (NYSE: LLY) has introduced its diabetes and weight-loss drug Mounjaro ...